Eagle Pharmaceuticals Price to Free Cash Flow Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals price to free cash flow ratio from 2013 to 2023. Price to free cash flow ratio can be defined as

Eagle Pharmaceuticals Price to Free Cash Flow Ratio 2013-2023 | EGRX

Eagle Pharmaceuticals price to free cash flow ratio from 2013 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$194.8B
Boston Scientific (BSX)$139.8B
Stryker (SYK)$139.4B
EssilorLuxottica (ESLOY)$110.1B
Medtronic (MDT)$103.4B
Lonza Group Ag (LZAGY)$43.7B
Haleon (HLN)$41.2B
GE HealthCare Technologies (GEHC)$38.7B
ResMed (RMD)$34.3B
Terumo (TRUMY)$28B
Koninklijke Philips (PHG)$24.3B
Zimmer Biomet Holdings (ZBH)$20.8B
Insulet (PODD)$19.1B
Baxter (BAX)$15B
Smith & Nephew SNATS (SNN)$10.5B
Bio-Rad Laboratories (BIO)$9.6B
BellRing Brands (BRBR)$9.1B
Demant (WILYY)$8.6B
Lantheus Holdings (LNTH)$6.7B
Haemonetics (HAE)$3.9B
ICU Medical (ICUI)$3.8B
Prestige Consumer Healthcare (PBH)$3.7B
Perrigo (PRGO)$3.3B
Envista Holdings (NVST)$3.2B
QuidelOrtho (QDEL)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
Neogen (NEOG)$2.7B
GN Store Nord (GNNDY)$2.6B
LeMaitre Vascular (LMAT)$2.1B
Green Thumb Industries (GTBIF)$1.6B